Gluvoid M Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10mg and Metformin 500mg, formulated for extended release. This dual-action agent is indicated for the management of type 2 diabetes mellitus in adults, particularly when glycemic control is inadequately achieved with diet and exercise alone. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, promotes renal glucose excretion, thereby reducing plasma glucose levels independently of insulin secretion. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glycemic control. The extended-release formulation allows for once-daily dosing, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Gluvoid M Tablet ER should be used as part of a comprehensive diabetes management plan, including diet modification and physical activity. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Monitoring of renal function and glycemic parameters is recommended during therapy. Potential adverse effects include urinary tract infections, genital mycotic infections, gastrointestinal disturbances, and rare but serious lactic acidosis. This combination therapy offers a synergistic approach to glycemic control, addressing multiple pathophysiological defects in type 2 diabetes.